Purple Biotech’s CAPTN-3 platform uses conditionally activated tri-specific antibody technology, part of a broader class of multispecific antibodies that has commanded $700 million+ upfront payments and multi-billion-dollar transactions across the pharmaceutical industry – yet the company trades at a single-digit-million valuation (NASDAQ: PPBT).
For decades, cancer treatment has faced a frustrating paradox: the human immune system is capable of recognizing and destroying cancer cells, yet tumors have evolved sophisticated ways to evade it. Checkpoint inhibitors like Keytruda helped “release the brakes” on the immune system, creating a revolution in oncology and generating tens of billions of dollars in annual sales. But many patients never respond, and among those who do, resistance often develops.
The next wave of cancer immunotherapy is no longer about simply removing immune restraints. It is about engineering precision immune weapons that engage multiple pathways at once and activate only where the cancer resides. This is where tri-specific antibodies come in – and where Purple Biotech (NASDAQ: PPBT) is placing its bet.
In simple terms, CAPTN-3 is designed to selectively turn on the immune system at the tumor (micro) environment – without triggering a body-wide immune attack.
Inside the CAPTN-3 Platform
Traditional monoclonal antibodies act like guided missiles aimed at a single target. Bispecific antibodies can engage two targets simultaneously. Purple’s CAPTN-3 platform goes a step further, creating tri-specific antibodies engineered to bind tumor cells while simultaneously recruiting both T cells and natural killer (NK) cells.
These immune cells play complementary roles. T cells excel at precision killing, while NK cells serve as the immune system’s rapid-response force, capable of attacking abnormal cells even when tumors evade classic immune recognition. Engaging both creates redundancy – if one pathway is suppressed, the other can still drive an immune response.
CAPTN-3 antibodies also feature conditional activation at the tumor site. A cleavable “cap” keeps the molecule largely inactive in circulation until enzymes in the tumor microenvironment remove it, activating the immune attack locally. The goal is to concentrate efficacy at the tumor site while reducing systemic toxicity, a key limitation of many immune-engaging therapies.
Purple’s lead program, IM1240, targets 5T4, an antigen overexpressed in multiple aggressive solid tumors. A second candidate, IM1305, targets TROP2, which is broadly expressed across breast, lung, gastrointestinal, and ovarian cancers.
Why Multispecific Antibodies Are Drawing Big Checks
Pharmaceutical companies have been paying extraordinary sums for multispecific antibody assets. In July 2025, AbbVie agreed to pay $700 million upfront for a tri-specific T-cell engager. In September 2025, Genmab announced an approximately $8 billion acquisition of Merus, known for its bispecific antibody platform. Bristol Myers Squibb partnered with BioNTech in a collaboration valued at up to $11.1 billion, focused on engineered antibody therapies.
If big pharma has already spent billions acquiring multispecific platforms, why would it need another?
Because cancer is not one disease but hundreds. A multi-specific antibody developed for blood cancers addresses a completely different patient population than one designed for solid tumors. Large pharmaceutical companies do not buy a single oncology asset and stop; they build portfolios across targets, mechanisms, and cancer types.
What differentiates CAPTN-3 is its dual immune-cell engagement combined with tumor-restricted activation. Many immune-engaging antibodies focus primarily on T cells alone. Purple’s approach aims to broaden the immune response while addressing toxicity – two challenges that have historically constrained this class.
In December 2025, Purple presented preclinical data at the ESMO Immuno-Oncology Congress showing that IM1240 induced cancer cell death in PD-1-resistant patient-derived tumor models and that the CAPTN-3 platform drives significant and durable in vivo tumor regression with IM1240 and IM1305. While preclinical data does not guarantee clinical success, it provides early evidence the platform may address tumors that have already failed checkpoint inhibitors.
Milestones That Matter
Purple plans to complete IND-enabling studies, submit an IND, and initiate a Phase 1 clinical trial during 2026. Each step represents a meaningful de-risking milestone.
In October 2025, the company announced a manufacturing milestone, demonstrating commercially viable production yields for IM1240 – an important achievement for complex tri-specific antibodies.
As of the end of the third quarter of 2025, Purple reported $10.5 million in cash, providing runway into the first half of 2027, enough to reach multiple upcoming inflection points.
When Price and Progress Diverge
Purple Biotech trades at a valuation of only a few million dollars, a stark contrast to companies such as Immunocore, which is commercial-stage with an FDA-approved T-cell-engaging therapy, and Zymeworks, which commands a multi-billion-dollar valuation based on its antibody engineering pipeline.
This gap is largely structural. Unlike these peers, Purple’s CAPTN-3 programs are pre-IND and preclinical, with first-in-human studies still ahead. While they are not direct competitors today, these companies illustrate the valuation ceiling that can emerge once complex immune-engaging platforms are clinically validated.
That disconnect may help explain why Wall Street analyst has assigned Purple Biotech a $34 price target (According to Tipranks).
Purple Biotech was trading at $0.66 a share as of market close on January 2, 2025/
Looking Ahead
As with any company of this stage, the risks are real, from clinical results to capital needs, these should not be ignored. At the same time, the multispecific antibody market is projected to grow from roughly $6 billion in 2024 to more than $11 billion by 2031, as pharmaceutical companies race to replenish pipelines ahead of major patent expirations. Amidst this backdrop, Purple Biotech has assembled what seems like differentiated platform, early evidence of activity in treatment-resistant tumor models, and a path toward clinical validation.
Subscribe for Similar Reports
Read More from The Finance Herald
- BRICS at Sea: Navigating Naval Unity Amidst Internal Tensions and Geopolitical Challenges
- The Hidden Costs of Federal Discrimination: Why the 8(a) Program Must Be Abolished
- Navigating the Complexities of Copyright in Modern Journalism: Ethical Considerations and Best Practices
- The Hidden Engine of Political Corruption: How Institutional Frameworks Facilitate Wealth Extraction in America
- China’s Tech Renaissance: Harnessing AI Innovation to Surge Ahead in 2026
- Antengene’s Next-Generation Cancer Arsenal Shows Promise as ADC Platform Delivers Strong Clinical Results
- Guarding the Dollar: Strategies to Sustain America’s Economic Power Amid Rising De-Dollarization Efforts
- Behind the Scenes: Iran and Israel Engage in Indirect Diplomacy Through Russian Mediation Amid Rising Tensions
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. The content above is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from Purple Biotech Ltd for promotional media services provided on an ongoing subscription basis and specifically during this period as detailed in the disclosures linked below. This content is for informational purposes only and does not constitute financial or investment advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. Market size figures, estimates, or price targets referenced in this article are quoted from publicly available sources believed to be reliable, however we do not independently verify or endorse them, and additional figures or estimates may exist., analyst price targets are subject to the full risks and disclosures in their original respective reports and may be subject to their own conflicts. This article has not been reviewed or approved by the issuer prior to publication nor should it be considered an official communication of the issuer.